Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Jun 1, 2011


Affymetrix announced this week that President and CEO Kevin King will step down at the end of June to "pursue other interests."

King will be replaced by Dionex President and CEO Frank Witney, who some years ago, served as Affymetrix's executive VP and COO.

BioMarker Strategies announced that Douglas Clark will become the company's chief medical officer and acting CEO starting July 1. Clark is currently a professor of pathology and oncology at The Johns Hopkins Medical Institutions, where from 2002 to 2010 he served as the director of the cytopathology division. He will be taking a leave of absence from Johns Hopkins to join BioMarker Strategies full time.

Additionally, BioMarker Strategies has appointed Glenn Miller, VP and head of strategy, portfolio, and alliances for personalized healthcare & biomarkers at AstraZeneca Pharmaceuticals, as the chairman of its board of directors. Miller previously served on BioMarker Strategies' scientific advisory board.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.